Sinovac Biotech (SVA) and BioMarin Pharmaceutical (BMRN) Critical Contrast

Sinovac Biotech (NASDAQ: SVA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Institutional and Insider Ownership

31.5% of Sinovac Biotech shares are held by institutional investors. Comparatively, 96.0% of BioMarin Pharmaceutical shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Sinovac Biotech and BioMarin Pharmaceutical, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech 0 0 0 0 N/A
BioMarin Pharmaceutical 0 6 16 0 2.73

BioMarin Pharmaceutical has a consensus price target of $113.52, suggesting a potential upside of 36.84%. Given BioMarin Pharmaceutical’s higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Sinovac Biotech.

Volatility & Risk

Sinovac Biotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sinovac Biotech and BioMarin Pharmaceutical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $72.43 million 6.04 -$1.07 million ($0.08) -95.86
BioMarin Pharmaceutical $1.12 billion 13.05 -$630.21 million ($0.90) -92.18

Sinovac Biotech has higher revenue, but lower earnings than BioMarin Pharmaceutical. Sinovac Biotech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.


This table compares Sinovac Biotech and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
BioMarin Pharmaceutical -12.45% -4.60% -3.09%


BioMarin Pharmaceutical beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply